Optos Celebrates Key Milestones: 25,000 Devices Installed Globally and Extensive Clinical Publications Achieved
-
- 2,500 clinical and peer-reviewed studies reached which span 235 disease states, demonstrating the clinical utility of Optos technology.
- The innovative technology from Optos offers the only single-capture ultra-widefield retinal imaging, expanding capabilities to diagnose, document, manage, and treat ocular pathology that may first present in the periphery.
Dunfermline, UK – 26 February 2024 – Optos PLC, a pioneering leader in retinal imaging technology, proudly announces a significant dual milestone achievement of over 25,000 devices installed worldwide, and the expansive collection of 2,500 clinical and peer-reviewed studies spanning 235 disease states. For more than 30 years, Optos has had a positive impact on the standard of retinal imaging technology and supported the advancement of patient care.
"This remarkable double milestone reflects the unwavering commitment that Optos has had to innovation and excellence in providing the best and clinically-relevant technology available, since our inception. The ongoing growth and recognition of the robust body of clinical research efforts underscores the dedication of our team to continue improving patient outcomes and driving development in ophthalmic care,” said Chief Executive Officer Robert Kennedy. "We extend our sincerest gratitude to our customers for their continued trust and support. Their feedback and partnership are invaluable as we strive to make retinal imaging more patient-friendly and accessible while empowering clinicians to deliver exceptional care."
As the only single capture, 200 degree, ultra-widefield retinal imaging technology, Optos continues to define the standard for comprehensive imaging beyond traditional constraints, crucial for diagnosing and managing a wide range of ocular conditions that otherwise may go undetected and undiagnosed. With a total of nine imaging modalities available across all device platforms, including the recent addition of optomap color rgb, natural color and optomap blue fundus autofluorescence imaging modalities, Optos furthers its technology offering. In addition, their combined imaging devices integrate ultra-widefield retinal imaging with optomap-guided OCT, providing clinicians with comprehensive insights into retinal health.
Consistently expanding their continuum of care, Optos technology seamlessly integrates into a variety of healthcare settings from telehealth to retina. With continued prioritization for eyecare providers on device ease of use and productivity, Optos technology streamlines workflow and enhances practice efficiency without compromising quality.
The commitment to patient and user-friendly solutions continues to drive modernization and excellence in ophthalmic imaging, ultimately improving patient outcomes and enhancing practice efficiency worldwide.
For more information about Optos and its industry-leading retinal imaging technology, visit the Optos website.
About Optos
Optos PLC, a subsidiary of Nikon Corporation, is the leading retinal imaging company. Its core technology, ultra-widefield (UWF™) high-resolution digital images (optomap®) capture approximately 82% and 200◦ of the retina, something no other device can do in a single image.
Optos has also developed integrated ultra-widefield retinal imaging with optomap-guided Optical Coherence Tomography (OCT). Optos devices facilitate the early detection, management, and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration.
More than 2,500 published clinical studies show the long-term value of optomap imaging in detection, diagnosis, treatment planning, and patient engagement.
Media Contact:
Cassy Dump
Shine Communications for Optos
Cassy@heyshine.com
(619) 971-1887
###